vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give vTv Therapeutics a “Moderate Buy” consensus: six analysts rate the stock a buy, one a strong buy, one a hold and one a sell. The average 12-month price target is $55.83, versus a recent price of $31.97.
• VTVT shares have traded between $18.97 and $44.00 over the past year, while the company’s latest quarterly loss of $1.05 per share missed the $0.97 consensus estimate.
• Institutional investors own 17.51% of the company, with Geode Capital Management increasing its stake by 84.3% and Goldman Sachs and 683 Capital Management establishing new positions.

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $55.8333.

Several equities research analysts recently weighed in on VTVT shares. Weiss Ratings cut shares of vTv Therapeutics from a "sell (d+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Wall Street Zen cut shares of vTv Therapeutics from a "buy" rating to a "sell" rating in a research note on Saturday, August 8th. Zacks Research raised vTv Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Monday, September 7th. Lifesci Capital upgraded shares of vTv Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 2nd. Finally, HC Wainwright reduced their target price on shares of vTv Therapeutics from $45.00 to $42.00 and set a "buy" rating on the stock in a research note on Thursday, August 6th.

vTv Therapeutics Price Performance

Shares of VTVT opened at $31.97 on Friday. The firm has a market cap of $125.96 million, a P/E ratio of -30.16 and a beta of 0.29. vTv Therapeutics has a 1 year low of $18.97 and a 1 year high of $44.00. The company has a 50 day simple moving average of $32.69 and a two-hundred day simple moving average of $34.46.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.08). On average, sell-side analysts anticipate that vTv Therapeutics will post -2.35 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in VTVT. Goldman Sachs Group Inc. purchased a new stake in shares of vTv Therapeutics in the 4th quarter worth approximately $221,000. 683 Capital Management LLC purchased a new position in vTv Therapeutics during the fourth quarter valued at approximately $731,000. Finally, Geode Capital Management LLC raised its stake in vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock worth $1,128,000 after buying an additional 12,896 shares in the last quarter. Hedge funds and other institutional investors own 17.51% of the company's stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.